TECOS
- 14,000 participants
- 12 sites in New Zealand
- 36 participating countries
TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin
A randomised, placebo controlled clinical Trial to Evaluate Cardiovascular Outcomes after treatment with Sitagliptin in patients with Type 2 Diabetes Mellitus and inadequate glycemic control on mono-or dual combination oral antihyperlycemic therapy (TECOS)
This is a multinational, placebo-controlled, double-blind, randomised, parallel-group pragmatic clinical trial. The purpose of this study is to assess the impact of sitagliptin therapy upon cardiovascular (CV) outcomes in a large population from a diverse group of countries and practice environments.